Ivan Cichowicz, MD
Geriatric Psychiatry · Boca Raton, FLNPI 1932312840
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $206,935 of the $254,786 with a category attached, or 81.2%. Johnson & Johnson accounts for 73.1% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $87,533, 3.7 times the $23,469 reported in 2019. Among geriatric psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 829 payments — averaging $307.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$186K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$52K
- Livanova USA, Inc.$7K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- plus $5K from 19 others
Across 293 payments — averaging $1803.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$458K
- Janssen Research & Development, LLC$59K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
What the payments were for
- Consulting fees$5,5002%
- Speaking & faculty fees$206,93581%
- Travel & lodging$23,4589%
- Food & beverage$18,8057%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 287 | $186,326 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 102 | $52,445 |
| Livanova USA, Inc. | 19 | $7,005 |
| Otsuka America Pharmaceutical, Inc. | 54 | $1,748 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,368 |
| Lundbeck LLC | 92 | $1,176 |
| AbbVie(2 entities) | 68 | $1,107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $1,030 |
| Alkermes, Inc. | 25 | $556 |
| Axsome Therapeutics, Inc. | 8 | $419 |
| Acadia Pharmaceuticals Inc | 4 | $246 |
| Neurocrine Biosciences, Inc. | 13 | $230 |
| Supernus Pharmaceuticals, Inc. | 5 | $181 |
| Idorsia Pharmaceuticals US Inc | 4 | $157 |
| E.r. Squibb & Sons, L.L.C. | 6 | $142 |
| Neuronetics, Inc. | 5 | $124 |
| Noven Pharmaceuticals, Inc. | 1 | $123 |
| Lilly USA, LLC | 2 | $118 |
| Vanda Pharmaceuticals Inc. | 3 | $83 |
| Almatica Pharma LLC | 4 | $72 |
| Noven Therapeutics, LLC | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$182,632
- CAPLYTA$51,137
- VNS Therapy Symmetry Model 8103 Generator$6,702
- REXULTI$807
- Auvelity$360
- Austedo XR$356
- AUSTEDO$249
- NUPLAZID$230
- VRAYLAR$214
- INVEGA SUSTENNA$139
- ABILIFY ASIMTUFII$133
- ABILIFY MAINTENA$133
- UZEDY$123
- Xelstrym$123
- QELBREE$114
- QUVIVIQ$107
How this compares
$254,786 in reported general payments places this provider in the 95th percentile of 33 geriatric psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 21 | $153,090 |
| AustedoDeutetrabenazine | 16 | $112,105 |
| IngrezzaValbenazine Tosylate | 12 | $102,089 |
| TrintellixVortioxetine Hydrobromide | 101 | $83,433 |
| RexultiBrexpiprazole | 38 | $70,983 |
| CaplytaLumateperone Tosylate | 41 | $65,217 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $19,545 |
| VraylarCariprazine Hcl | 11 | $17,115 |
| Vilazodone Hcl | 177 | $14,860 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $14,244 |
| Lurasidone Hcl | 69 | $12,283 |
| Aripiprazole | 207 | $12,097 |
| DayvigoLemborexant | 31 | $12,057 |
| Bupropion XlBupropion Hcl | 216 | $5,307 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 97 | $4,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $246 | $153,09021 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,368 | $112,10516 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $230 | $102,08912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,030 | $83,433101 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,748 | $70,98338 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $52,445 | $65,21741 claims |
| Alkermes, Inc.Lybalvi | $556 | $19,54513 claims |
| AbbVieVraylar | $1,107 | $17,11511 claims |
| Axsome Therapeutics, Inc.Auvelity | $419 | $14,24415 claims |
| Lilly USA, LLCOlanzapine | $118 | $2,975107 claims |
| Almatica Pharma LLCSertraline Hcl | $72 | $96892 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 geriatric psychiatry providers in Florida.
Other geriatric psychiatry in Boca Raton
- Helia Ibarra-AlosBoca Raton$756
- Louis GoldBoca Raton$0
- Amanda SmithTampa$10K
- Julio MachadoMiami$8K
- Luis VinuelaMelbourne$7K
- Nandita JoshiJacksonville$3K
- Ramon PinoGainesville$2K
- Willy PhiliasWest Palm Beach$1K
- Luis AllenOrlando$1K
- Barbara SrurSarasota$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.